MAIA Biotechnology, Inc. has entered into a significant stock purchase agreement with Prevail Partners, LLC, involving the issuance and sale of $587,905 worth of its common stock. The agreement, signed on June 24, 2025, includes an upfront payment of $58,800.3333 in shares and 36 equal tranche payments of $14,697.333 each. The stock will be sold at a minimum share price of $1.74, with a maximum issuance of 337,876 shares, adhering to a 19.99% issuance cap. The proceeds from this agreement will be used to fund technologies and services provided by Prevail Infoworks under a previously established Master Service and Technology Agreement. These services are crucial for a Phase 3 study evaluating THIO in combination with cemiplimab versus chemotherapy for advanced non-small cell lung cancer treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.